ReviewActa pharmacologica Sinica2026
GluD1 at the synaptic crossroads: from domain structure to circuit dysfunction.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular continuity between axon guidance and synaptic function.Molecules and cells · 2026Review
- Molecular basis for ligand-gating of the human GluD1 receptor.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
For several decades, the glutamate delta-1 receptor (GluD1) has remained an enigmatic entity among ionotropic glutamate receptors (iGluRs), primarily due to its lack of classical ion channel activity. Recent advancements have redefined GluD1 as a multifunctional synaptic organizer, essential for the development, plasticity, and behavioral regulation of both excitatory and inhibitory circuits. In this review, we synthesize recent progress at the structural, molecular, and circuit levels to reconceptualize GluD1 as a pivotal signaling scaffold that functions through non-ionotropic mechanisms. We emphasize the modular architecture of GluD1, encompassing the amino-terminal domain, ligand-binding domain, transmembrane region, and C-terminal domain to elucidate how each component uniquely contributes to synaptic function. Evidence from genetic models and structural biology underscores GluD1's involvement in transsynaptic adhesion, ligand-dependent conformational signaling, and intracellular pathway modulation. Additionally, we discuss its emerging clinical significance, with GRID1 mutations associated with neurodevelopmental and psychiatric disorders, and recent findings implicating GluD1 dysfunction in chronic pain. Finally, we explore domain-specific therapeutic strategies, including peptide mimetics, synthetic organizers, and non-ionotropic modulators, positioning GluD1 as a promising target for circuit-level intervention in brain disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.